Charles River Laboratories International (NYSE:CRL) CAO Sells 6,645 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CAO Michael Gunnar Knell sold 6,645 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the transaction, the chief accounting officer directly owned 11,852 shares in the company, valued at $3,086,023.76. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $8.85 during trading hours on Monday, reaching $276.34. The company had a trading volume of 1,025,309 shares, compared to its average volume of 924,952. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The stock has a fifty day moving average of $214.85 and a 200-day moving average of $189.04. The company has a market capitalization of $13.19 billion, a price-to-earnings ratio of -56.98, a PEG ratio of 2.77 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $277.07.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm’s revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently made changes to their positions in CRL. Cardinal Capital Management lifted its stake in Charles River Laboratories International by 0.6% in the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after acquiring an additional 62 shares during the last quarter. Asset Management One Co. Ltd. grew its position in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock worth $375,000 after acquiring an additional 71 shares in the last quarter. Glenmede Trust Co. NA increased its stake in shares of Charles River Laboratories International by 2.8% during the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after purchasing an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Charles River Laboratories International by 1.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after purchasing an additional 80 shares during the last quarter. Finally, Advisory Services Network LLC raised its holdings in shares of Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after purchasing an additional 83 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on CRL shares. Royal Bank Of Canada lifted their target price on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a research note on Thursday. Mizuho set a $264.00 price target on shares of Charles River Laboratories International in a report on Monday. TD Cowen lifted their price target on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research report on Monday. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday. Finally, JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $180.00 to $310.00 in a report on Thursday. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $255.65.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.